JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laster, M. J.
Right arrow Articles by Eger, E. I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Laster, M. J.
Right arrow Articles by Eger, E. I., II

Anesth Analg 2005;100:1542
© 2005 International Anesthesia Research Society
doi: 10.1213/01.ANE.0000149047.06813.41


LETTER TO THE EDITOR

Measurement of Isoflurane and Desflurane Degradation

Michael J. Laster, DVM, Patricia Roth, MD, and Edmond I. Eger, II, MD

Department of Anaesthesia; University of California, San Francisco; San Francisco, CA; egere{at}anesthesia.ucsf.edu

In Response:

Dunning and Woehlck have correctly taken us to task for neglecting the effect of desflurane degradation products on the RGM 5250 determination of desflurane (and isoflurane) concentration. Using gas chromatography, we confirmed the correctness of their criticism by measuring the concentrations of desflurane in the presence of desiccated Baralyme®. Duplicate measurements (two runs) supplied the data for desflurane presented in Figure 1. As in the previous study (1), peak temperatures of 100°C were reached 20–30 min after initiating delivery of 9% desflurane. Temperatures declined thereafter, despite appreciable continuing desflurane degradation for up to an hour of desflurane delivery.



View larger version (32K):
[in this window]
[in a new window]
 
Figure 1. Degradation of 1.5 MAC (2.8%) sevoflurane exceeds degradation of 1.5 MAC isoflurane (1.8%), which, in turn, exceeds degradation of 1.5 MAC desflurane (9%). Percent degradation was calculated as 100 times (the difference between the delivered and end-tidal concentrations) divided by the delivered concentration. Concentrations in the case of desflurane were measured by gas chromatography, whereas concentrations of sevoflurane and isoflurane were measured by the Ohmeda RGM 5250 (Louisville, CO). For the reasons offered by Dunning and Woehlck, the values for isoflurane probably are underestimated.

 

Although the data presented in Figure 1 quantitatively differ greatly from the data presented in a similar figure in our original report (Fig. 5) (1), the qualitative implications are unchanged. Degradation of desflurane, and to a lesser extent isoflurane, is not sustained. In contrast, degradation of sevoflurane continues at appreciable levels for the duration of sevoflurane administration (note that data for the full 2 hours are not presented because fire occurred in one run, and inclusion of those data would skew the results). The data for desflurane and isoflurane are consistent with an action of potassium hydroxide (KOH) on these anesthetics. The limited presence of KOH (5% of base), and its consequent rapid depletion, restricts the degradation of desflurane and isoflurane. Degradation of desflurane decreases faster than degradation of isoflurane because the concentration of desflurane is three times greater, thus exhausting the stores of KOH sooner. The continuing degradation of sevoflurane suggests that barium hydroxide and/or calcium hydroxide, as well as KOH, degrade sevoflurane.

The important message of our previous report (1) remains unchanged by the present correction. Sevoflurane degradation by desiccated Baralyme® can lead to temperatures exceeding 150°C and to fire in the anesthetic circuit. In contrast, degradation of desflurane and isoflurane by desiccated Baralyme® leads to lower temperatures (peaks of 100°C), and these lower temperatures do not lead to fire. As an aside, we note that a concern that fires from sevoflurane degradation may be more likely with Baralyme® than soda lime has resulted in the withdrawal of desiccated Baralyme® from commercial use. Whether this problem extends to soda lime remains to be determined.

[Dr. Eger is a paid consultant to Baxter Healthcare, the manufacturer of desflurane.]

Reference

  1. Laster M, Roth P, Eger EI II. Fires from the interaction of anesthetics with desiccated absorbent. Anesth Analg 2004;99:769–74.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laster, M. J.
Right arrow Articles by Eger, E. I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Laster, M. J.
Right arrow Articles by Eger, E. I., II


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press